Revvity Sr141716a,

Revvity SR141716A acts as an antagonist at the cannabinoid CB₁ receptor, and is used to treat obesity. Cannabinoid receptors are a group of GPCRs that are potential drug targets for smoking sessation and weight loss. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET1158: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Bisset, K.M., Dhopeshwarkar, A.S., Liao, C., Nicholson, R.A. (2011) The g protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: Inhibition by phthalate esters in vitro, Neurochemistry International, 59 (5): 706-713.Liao, C., Zheng, J., David, L. S. and Nicholson, R. A. (2004), Inhibition of Voltage-Sensitive Sodium Channels by the Cannabinoid 1 Receptor Antagonist AM 251 in Mammalian Brain. Basic & Clinical Pharmacology & Toxicology, 94: 73–78.